Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

about

Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

Item

http://www.wikidata.org/entity/Q39698999

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

@en

Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

@nl

type

Item

label

Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

@en

Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

@nl

prefLabel

Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

@en

Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

@nl

P1476

Expression of VEGFR and PDGFR-α/-β in 187 canine nasal carcinomas.

@en

P2093

D Chandry

http://www.w3.org/2001/XMLSchema#string

D Killick

http://www.w3.org/2001/XMLSchema#string

I Gramer

http://www.w3.org/2001/XMLSchema#string

L Blackwood

http://www.w3.org/2001/XMLSchema#string

M Marrington

http://www.w3.org/2001/XMLSchema#string

T Scase

http://www.w3.org/2001/XMLSchema#string

P2860

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

Normalization of the vasculature for treatment of cancer and other diseases.

Expression of peroxisome proliferator-activated receptor gamma (PPAR-gamma) in canine nasal carcinomas.

Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma

Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.

Hypoxia-induced angiogenesis: good and evil

P304

1041-1050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VCO.12245

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27278115

http://www.w3.org/2001/XMLSchema#string